Research suggests that GLP-1 receptor agonists may be associated with a lower incidence of breast cancer. This potential link has been identified, although the nature and extent of the relationship are not fully detailed. The findings indicate a possible connection between GLP-1 RAs and reduced breast cancer incidence.